ArticleThe Journal of clinical endocrinology and metabolism2026
The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults.
Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Latent autoimmune diabetes in two young female patients successfully treated with oral semaglutide and basal insulin.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
introductionSemaglutide, a GLP-1R agonist (GLP-1RA), has demonstrated high efficacy in the management of type 2 diabetes. Few data in literature are available regarding the use of this agent in patients affected by latent autoimmune diabetes in adults (LADA). The purpose of this study is to analyze the efficacy of semaglutide use in patients affected by LADA. MATERIALS AND
methodsIn this retrospective study, we collected and analyzed data of 80 patients with LADA treated with semaglutide, either oral or subcutaneous, as an add-on therapy to insulin. Laboratory and clinical parameters and metrics from continuous glucose monitoring were collected where available.
resultsAmong 80 patients, 68 continued semaglutide (57/68 oral and 11/68 subcutaneous) for at least 6 months, whereas 12/80 patients discontinued treatment. After 6 months, semaglutide users showed statistically significant reduction in glycated hemoglobin, body mass index, and insulin total daily dose. Interestingly, serum C-peptide levels and the time-in-range values increased, without changes in the time below range. Subjects with residual β-cell function showed a higher body mass index and insulin total daily dose reduction. Moreover, the subgroup of subjects with preserved β-cell mass showed a greater improvement in time in range as compared to those with poor C-peptide production. Finally, 14/68 subjects suspended insulin bolus administration after starting semaglutide.
conclusionSemaglutide as an add-on treatment to insulin exerted relevant clinical beneficial effects on the glycometabolic control in patients with LADA. These effects are enhanced in those patients with preserved β-cell function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.